Tailoring cancer treatment to genetic profile extends lives, study finds

21 Tips for Traveling With Diabetes
July 4, 2018
Hepatitis C: The silent killer
July 5, 2018
Show all

Tailoring cancer treatment to genetic profile extends lives, study finds

Genetic sequencing of patients’ tumors can improve cancer outcomes.

Cancer patients with diseases that are difficult to treat may live longer if doctors engage in genetic sequencing and then match treatment to their illness, a long-term “precision medicine” study has found.

The study represents part of a push in cancer treatment to personalize medicine for specific patients, matching known tumor mutations to treatments in an effort to extend patients’ lives. It is the first long-term study to compare tailored methods to traditional, more generic treatment.

“All patients should have access to next generation sequencing and I believe in the next few years we are going to see this approach dramatically improving outcomes,” said Apostolia Maria Tsimberidou, a professor at the University of Texas MD Anderson Cancer Center, who led the research.

“We need to know what is really causing these diseases so we can treat them properly.”

The study was presented at the annual meeting of the American Society of Clinical Oncology (Asco) in Chicago, the world’s largest gathering of cancer specialists.

The study looked at more than 3,700 people with cancer that had proved difficult to treat and who had already undergone other types of treatments. Their ages ranged from 16 to 86, with a median of 57.

Included in the study were gastrointestinal (24.2%), gynecological (19.4%), breast (13.5%), skin (11.9%) and lung (8.7%) cancers.

Of those patients, 1,307 had a known mutation, and 711 received treatment based on that genetic profile. Those patients were twice as likely to live three years (15%) versus those who did not receive tailored treatments (7%). Patients were also six times more likely to live 10 years if they received tailored treatment, at 6% of the sample compared with just 1% for those who received general treatment.

Another, more comprehensive trial is due to take place at the MD Anderson Cancer Center, which will address an admitted shortcoming in the previous study, by using randomized trials.

Tsimberidou said her own clinic had witnessed the potential of personalized cancer medicines. One patient has been kept alive despite being diagnosed in 2011 with an aggressive form of brain cancer called glioblastoma. The same cancer killed the former US vice-president Joe Biden’s son, Beau, who died in 2015, and former British cabinet minister Tessa Jowell, last month.

Read on: Tailoring cancer treatment to genetic profile extends lives, study finds | Science | The Guardian

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.